SCHEMBL7909509

SCHEMBL7909509

COc1ccc(C(F)(F)F)c(OC)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
CA7 P43166 1/20 0.56
CA9 Q16790 1/20 0.56
CA14 Q9ULX7 1/20 0.56
MRGPRX4 Q96LA9 1/20 0.49
ALDH1A1 P00352 4/20 0.48
CYP1A1 P04798 3/20 0.48
CYP1A2 P05177 3/20 0.48
CYP1B1 Q16678 3/20 0.48
CYP3A4 P08684 2/20 0.48
HTR2A P28223 2/20 0.45
CYP2E1 P05181 1/20 0.44
CYP2C8 P10632 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2A6 P11509 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP4B1 P13584 1/20 0.44
CYP2B6 P20813 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31193485 1.00 CA12 (0.56) CA12CA1CA2CA7CA9
SCHEMBL16838796 0.83 EPHX2 (0.46) CA12CA1CA2CA7CA9
SCHEMBL12422332 0.83 CA12 (0.56) CA12CA1CA2CA7CA9
SCHEMBL29775318 0.83 CA12 (0.56) CA12CA1CA2CA7CA9
SCHEMBL4628852 0.83 EPHX2 (0.46) CA12CA1CA2CA7CA9
SCHEMBL29427761 0.82 ALDH1A1 (0.49) CA12CA1CA2CA7CA9
SCHEMBL10656799 0.82 ALDH1A1 (0.49) CA12CA1CA2CA7CA9
SCHEMBL17287097 0.81 CA12 (0.48) CA12CA1CA2CA7CA9
SCHEMBL8784810 0.81 CA12 (0.58) CA12CA1CA2CA7CA9
SCHEMBL31525792 0.81 CA1 (0.58) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062393-A1 Compounds CTXT PTY LTD (AU) 2026-03-05 US disclosed
US-12365655-B2 Compounds CTXT PTY LTD (AU) 2025-07-22 US disclosed
EP-4335439-A2 COMPOUNDS CTXT PTY LTD (AU) 2024-03-13 EP disclosed
EP-3810602-B1 COMPOUNDS CTXT PTY LTD (AU) 2023-11-01 EP disclosed
EP-3810602-B1 COMPOUNDS CTXT PTY LTD (AU) 2023-11-01 EP disclosed
US-20220153710-A1 Compounds CTXT PTY LTD (AU) 2022-05-19 US disclosed
US-20220153710-A1 Compounds CTXT PTY LTD (AU) 2022-05-19 US disclosed
EP-3810602-A1 COMPOUNDS CTXT Pty Limited (AU) 2021-04-28 EP disclosed
CN-112334466-A Compound (I) CTXT私人有限公司 2021-02-05 CN disclosed
US-20200039945-A1 Compounds CTXT PTY LIMITED (AU) 2020-02-06 US disclosed
EP-3215476-B1 METHOD FOR PREPARATION OF FLUORO, CHLORO AND FLUOROCHLORO ALKYLATED COMPOUNDS BY HOMOGENEOUS CATALYSIS LONZA AG (CH) 2018-02-28 EP disclosed
US-20170320878-A1 METHOD FOR PREPARATION OF FLUORO, CHLORO AND FLUOROCHLORO ALKYLATED COMPOUNDS BY HOMOGENEOUS CATALYSIS LONZA LTD (CH) 2017-11-09 US disclosed
US-20170320878-A1 METHOD FOR PREPARATION OF FLUORO, CHLORO AND FLUOROCHLORO ALKYLATED COMPOUNDS BY HOMOGENEOUS CATALYSIS LONZA LTD (CH) 2017-11-09 US disclosed
US-9809596-B1 Method for preparation of fluoro, chloro and fluorochloro alkylated compounds by homogeneous catalysis LONZA LTD. (CH) 2017-11-07 US disclosed
US-9809596-B1 Method for preparation of fluoro, chloro and fluorochloro alkylated compounds by homogeneous catalysis LONZA LTD. (CH) 2017-11-07 US disclosed
US-9422240-B2 Partially saturated nitrogen-containing heterocyclic compound TAISHO PHARMACEUTICAL CO., LTD (JP) 2016-08-23 US disclosed
WO-2016071425-A1 METHOD FOR PREPARATION OF FLUORO, CHLORO AND FLUOROCHLORO ALKYLATED COMPOUNDS BY HOMOGENEOUS CATALYSIS LONZA LTD (CH) 2016-05-12 WO disclosed
US-20150175541-A1 PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-06-25 US disclosed
US-6215021-B1 TRIFLUOROMETHYL DIPHENYLSULFONIUM TRIFLATE DERIVATIVES IDAHO RESEARCH FOUNDATION, INC. 2001-04-10 US disclosed
US-4731450-A Process for perfluoroalkylation of aromatic derivatives RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1988-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170320878-A1 METHOD FOR PREPARATION OF FLUORO, CHLORO AND FLUOROCHLORO ALKYLATED COMPOUNDS BY HOMOGENEOUS CATALYSIS AOC1, HDHD5, DDT CA12 1884/4885CA1 1916/4885CA2 3443/4885
US-20220153710-A1 Compounds SLC10A1, ABCB11, PCSK9 CA12 364/4885CA1 881/4885CA2 255/4885
US-20150175541-A1 PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND EGLN2, EGLN3, EGLN1 CA12 3013/4885CA1 2493/4885CA2 791/4885
US-20200039945-A1 Compounds SLC10A1, ABCB11, PCSK9 CA12 365/4885CA1 881/4885CA2 256/4885
US-20260062393-A1 Compounds SCN2B, ABCB11, SCN1B CA12 906/4885CA1 1778/4885CA2 199/4885
US-12365655-B2 Compounds SLC10A1, ABCB11, PCSK9 CA12 365/4885CA1 881/4885CA2 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.